Results were presented in a poster presentation entitled "Novel synthetic RORgamma agonist compounds as a potential anti-tumor therapeutic approach" and will be highlighted in an oral presentation on
As part of this collaboration, Idera and PPMD intend to work together to conduct preclinical studies and develop a clinical development strategy for an investigational TLR antagonist candidate.
Staphefekt is the first endolysin available for human use on intact skin. Endolysins are enzymes that originate from bacteriophages (phages), microorganisms that kill only bacteria. In nature, phages
NK1 receptor antagonists are administered in combination with a 5-HT3 receptor antagonist for the prevention of CINV. Heron Therapeutics’ lead investigational product candidate, SUSTOL® (granisetron injection, extended release),
The FDA is expected to review the submission and comment on the proposed study population, clinical endpoints, and statistical analyses within 30 to 45 days. The submission of
These methods further strengthen ViaCyte’s intellectual property platform, providing alternative ways to produce pancreatic progenitor and endocrine cells that have potential for use in cell replacement therapies. Pancreatic
Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme, a Sanofi company. Cerdelga was approved by the U.S. Food and Drug
The trial is designed to assess ThermoDox in combination with radiofrequency ablation standardized to 45 minutes (sRFA) versus sRFA alone to treat patients with non-resectable HCC lesions. ThermoDox
The MMRF, in collaboration with the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI), pharmaceutical, biotech and diagnostic industry members, academic center leaders and patients,
Under the terms of the agreement, Invetech will provide Argos with services, technology and equipment to support the design, development, supply and maintenance of customized manufacturing systems to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.